Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ENTRADA THERAPEUTICS, INC. reported revenue of $25M, down 87.9% year over year. Operating margin was -621.1% and net margin -565.5%, on a free-cash-flow margin of -509.6% with capital expenditure at 4.1% of revenue. Every figure is computed directly from TRDA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $25M | -621.1% | -565.5% |
| FY2024 | $211M | 22.3% | 31.1% |
| FY2023 | $129M | -2.5% | -5.2% |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
How does TRDA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.